BD Predicts Doubling Of Infusion Therapy In Wake Of Ohmeda Acquisition
This article was originally published in The Gray Sheet
Becton Dickinson expects to more than double its infusion therapy (IT) business to $500 mil. in 1999, the first full fiscal year following the company's acquisition of Ohmeda's medical device division, IT worldwide division president Bob Adrion told analysts April 28 in New York City. For 1997, BD reported IT product sales of $228 mil.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.